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Technetium-99 Conjugated with Methylene Diphosphonate Ameliorates
Ovariectomy–induced Osteoporotic Phenotype without Causing Osteonecrosis in
the Jaw
Abstract
Technetium-99 conjugated with methylene diphosphonate (99Tc-MDP) is a novel bisphosphonate
derivative without radioactivity and has been successfully used to treat arthritis in China for years. Since
bisphosphonate therapy has the potential to induce bisphosphonate-associated osteonecrosis of the jaw
(BRONJ), we examine whether 99Tc-MDP represents a new class of bisphosphonate for anti-resorptive
therapy to ameliorate estrogen deficiency–induced bone resorption with less risk of causing BRONJ. We
showed that 99Tc-MDP-treated ovariectomized (OVX) mice had significantly improved bone mineral
density (BMD) and trabecular bone volume in comparison to the untreated OVX group by inhibiting
osteoclasts and enhancing osteogenic differentiation of bone marrow mesenchymal stem cells
(BMMSCs). To determine the potential of inducing BRONJ, 99Tc-MDP/dexamethasone (Dex) or
zoledronate/Dex were administered into C57BL/6J mice via the tail vein, followed by extraction of
maxillary first molars. Interestingly, 99Tc-MDP treatment showed less risk to induce osteonecrosis in the
maxillary bones compared to zoledronate treatment group, partially because 99Tc-MDP neither
suppressed adaptive regulatory T cells (Tregs) nor activated the inflammatory T-helper-producing
interleukin 17 cells (Th17). Taken together, our findings demonstrate that 99Tc-MDP therapy may be a
promising approach in the treatment of osteoporosis with less risk of causing BRONJ.
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Abstract
Technetium-99 conjugated with methylene diphosphonate (99Tc-MDP) is a novel bisphosphonate
derivative without radioactivity and has been successfully used to treat arthritis in China for years.
Since bisphosphonate therapy has the potential to induce bisphosphonate-associated osteonecrosis
of the jaw (BRONJ), we examine whether 99Tc-MDP represents a new class of bisphosphonate for
anti-resorptive therapy to ameliorate estrogen deficiency–induced bone resorption with less risk of
causing BRONJ. We showed that 99Tc-MDP-treated ovariectomized (OVX) mice had
significantly improved bone mineral density (BMD) and trabecular bone volume in comparison to
the untreated OVX group by inhibiting osteoclasts and enhancing osteogenic differentiation of
bone marrow mesenchymal stem cells (BMMSCs). To determine the potential of inducing
BRONJ, 99Tc-MDP/dexamethasone (Dex) or zoledronate/Dex were administered into C57BL/6J
mice via the tail vein, followed by extraction of maxillary first molars. Interestingly, 99Tc-MDP
treatment showed less risk to induce osteonecrosis in the maxillary bones compared to zoledronate
treatment group, partially because 99Tc-MDP neither suppressed adaptive regulatory T cells
(Tregs) nor activated the inflammatory T-helper-producing interleukin 17 cells (Th17). Taken
together, our findings demonstrate that 99Tc-MDP therapy may be a promising approach in the
treatment of osteoporosis with less risk of causing BRONJ.
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Introduction
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Postmenopausal osteoporosis is the most common type of osteoporosis, in which estrogen
deficiency-induced T cell activation promotes osteoclastogenesis to reduce bone mineral
density (BMD) [1–5]. Although bisphosphonate therapy has been widely used in clinics,
concerns have been raised by the emergence of side effects such as bisphosphonate-related
osteonecrosis of the jaw (BRONJ). Currently, there is no appropriate therapy available in
clinics, because we still do not understand the underlying pathophysiological mechanism of
BRONJ [1, 6–8]. By establishing a BRONJ mouse model, we recently found that
administration of zoledronate causes BRONJ-like disease in mice, in part by suppressing
adaptive regulatory T cells, Tregs, while, at the same time, activating the inflammatory Thelper-producing interleukin 17 cells, Th17 [7]. These results suggest that BRONJ is a
disease associated with immune dysfunction triggered by administration of bisphosphonate
and trauma. Therefore, it is critical to develop appropriate drugs with the capacity of
ameliorating osteoporotic phenotype with minimal risk to induce BRONJ.

NIH-PA Author Manuscript

Technetium-99 conjugated with methylene diphosphonate (99Tc-MDP) is a patented
antiinflammatory drug, and it has been used for a safe treatment for rheumatoid arthritis
(RA) and ankylosing spondylitis (AS) in China since 1997 [9]. Since 99Tc-MDP is a
radioactive-safe decay product of 99mTc-methylene diphosphonate (99mTc-MDP) that has
been widely used in bone scintigraphy as a radioactive agent with no significant adverse
effects in clinical use. It has been proved that 99Tc-MDP treatment can inhibit macrophage
infiltration together with downregulation of proinflammatory cytokines, including TNF-α
and IL1-β, ICAM-1, and MMPs [9-10]. Since 99Tc-MDP has both potential antiresorptive
effects as a bisphosphonate derivative and anti-inflammatory effects by inhibiting
proinflammatory cytokines, it is reasonable to hypothesize that 99Tc-MDP might offer
therapeutic effect for osteoporosis. Also, it is important to evaluate whether 99Tc-MDP
treatment affects balance between Tregs and Th17, since Treg/Th17 cell imbalance is an
important contributing factor for BRONJ [7]. In this study, we demonstrate that
administration of 99Tc-MDP results in improvement of BMD in ovariectomy (OVX)induced osteoporotic mice by inhibiting osteoclasts and enhancing osteogenesis of bone
marrow mesenchymal stem cells (BMMSCs). In contrast to zolendronate, we also show
that 99Tc-MDP treatment neither increases Th17 levels nor decreases Treg levels, thus
avoiding the onset of BRONJ in a mouse model.

Materials and Methods
OVX and BRONJ Mouse Models

NIH-PA Author Manuscript

Female C3H/HeJ strain mice (8-week-old) were purchased from Jackson Laboratory (Bar
Harbor, ME, USA). Generation of OVX mice was performed as described previously [11]
and age-matched C3H/HeJ mice receiving sham operation served as control (n=8). In
experimental groups (n=11), 99Tc-MDP (Yunke, Chengdu, Sichuan, China. 62.5μg/kg, once
per week) or zoledronate (Zometa, Novartis Oncology, East Hanover, NJ, USA. 62.5μg/kg,
once per week) were administrated intravenously 2 weeks post-OVX for 2 weeks. Mice
were sacrificed 5 weeks after OVX.
To generate the BRONJ mouse model, C57BL/6J mice (Jackson Laboratory, Bar Harbor,
ME, USA) received intravenous zoledronate (125μg/kg, twice per week) with/without
dexamethasone (Dex) (Sigma-Aldrich Co, St. Louis, MO, USA, 5mg/kg, twice per week,
n=11 and 10, respectively). Due to the different metabolic rates between mice and human, a
body surface area calculation method was recommended by FDA (http://www.fda.gov/
downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm078932.pdf).
The dosage used in mice needs to be at least 12 times more than that in humans.
Calcif Tissue Int. Author manuscript; available in PMC 2013 December 04.
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Therefore, we used 12-13 times higher dosage of zoledronate to induce BRONJ mouse
model. Mice were injected with 99Tc-MDP (125μg/kg, twice each week) with/without Dex
(5mg/kg, twice each week, n=10) via the tail vein. One week after injection, maxillary first
molars were extracted under deep anesthesia by i.p. injection of ketamine (Ketaject, 95mg/
kg; Phoenix, St. Joseph, MO, USA) and xylazine (Xylaject, 5mg/kg; Phoenix). Two weeks
after tooth extraction, the intact maxillas were harvested en bloc. A total of 6 doses of
zoledronate/Dex and 99Tc-MDP/Dex were administered for the 2-week follow-up groups,
respectively. Untreated mice with tooth extraction were used as controls.
All animal experiments were performed under institutionally approved protocols for the use
of animal research at the University of Southern California (USC) (USC#11141, 10941 and
11327).
Antibodies and Reagents
Anti-alkaline phosphatase (ALP) antibodies were purchased from Santa Cruz Biotechnology
(Santa Cruz, CA, USA). Anti-β-actin antibody was purchased from Sigma-Aldrich Co.
Purified mouse anti-peroxisome proliferator-activated receptor γ (PPARγ) IgG MAb and
goat anti-lipoprotein lipase (LPL) IgG were from Santa Cruz Biotechnology (Santa Cruz,
CA). APC-conjugated anti-CD4, PE-conjugated anti-FoxP3 and PE-conjugated anti-IL17
antibodies were purchased from eBioscience (San Diego, CA).

NIH-PA Author Manuscript

Enzyme-linked Immunosorbent (ELISA) Assay
Serum markers of bone turnover, including receptor activator of nuclear factor kappa-B
ligand (RANKL) and osteoprotegerin (OPG), were measured using ELISA kits purchased
from RD System (Minneapolis, MN, USA) according to the manufacturer's instructions.
MicroCT Analysis
Femurs were harvested and analyzed by Inveon micro-CT system (Siemens AG, Germany).
Cross sectional volumetric bone mineral density (BMD) was measured at right femur middiaphysis with a density phantom. The specimens were scanned with the following
parameters: 14μm resolution, 80 kV voltage, 80 μA current, 2730 ms exposure time. Using
3-dimensional images, a region of interest in secondary spongiosa was manually drawn near
the endocortical surface, and trabecular thickness (Tb.Th, mm), bone volume/total volume
(BV/TV, %) and bone trabecular number (Tb.n) were assessed as a cancellous bone
morphometric parameters.
Bone Histological and Histomorphometric Analysis

NIH-PA Author Manuscript

For histological and histomorphometric analysis, femurs and tibias were fixed with 4%
paraformaldehyde after euthanization. Samples were decalcified with 10% EDTA (pH 8.0),
embedded in paraffin and stained with hematoxylin and eosin (H&E) for sections, followed
by calculation of trabecular bone volume percentage (Tb percentage, %) using ImageJ
software in the area of interest. Trabecular bone only was analyzed by not including sections
within two fields from either the growth plate or the cortices. Care was taken to analyze the
same, standard site in every animal. At least 5 fields (1 × 1 mm area of bone) per sample
were counted. Tartrate-resistant acid phosphate (TRAP) staining was performed according
to a previous report [12]. For quantification of bone resorption in the bones, five
representative images were analyzed by using ImageJ software. The results were shown as
osteoclastic surface per mm bone surface (Oc.S/BS). All the parameters were assessed by a
single, experienced technician, blinded to the treatment group of the mice, as previously
described [13-14]. Kidney, liver and bladder were also harvested from each mouse, and HE
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staining was used to detect whether there is any pathological change. Histological analysis
in BRONJ model was performed as described previously [7].
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Mouse BMMSC and Jaw Bone MSC (JBMSC) Culture
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CFU-F and BrdU Incorporation Assays

Bone marrow cells were flushed out from bone cavity of femurs and tibias with 2% heatinactivated fetal bovine serum (FBS; Equitech-Bio, Kerrville, TX, USA) in PBS. Single-cell
suspension was obtained by passing through 70 m cell strainers (BD Bioscience, Franklin
Lakes, NJ). JBMSCs were isolated from mouse mandibles according to our previous report
[28]. Briefly, both attached soft tissues and teeth were removed from the mandibles and all
nucleated cells from mandibles were obtained by digestion with 3 mg/ml collagenase type I
(Worthington Biochem, Lakewood, NJ, USA) and 4 mg/ml dispase II (Roche Diagnostic,
Indianapolis, IN, USA) for 60 min at 37°C. Both BMMSCs and JBMSCs were seeded and
cultured with alpha minimum essential medium (α-MEM, Invitrogen Co., Carlsbad, CA,
USA) supplemented with 20% FBS, 2 mM L-glutamine (Invitrogen), 55 μM 2mercaptoethanol (Invitrogen), 100 U/ml penicillin, and 100 μg/ml streptomycin
(Invitrogen). Attached cells were cultured for 16 days. To confirm mesenchymal stem cell
characteristics, we used flow cytometric analysis to show that these MSCs were positive for
CD73, CD90, CD105, CD146, CD166, Sca-1 and SSEA-4, but negative for CD11b, CD31,
CD34 and CD45.

P1 MSCs were seeded in T-25 culture flasks (Nalgene Nunc, Rochester, NY, USA). After
16 days, the flasks were stained with a mixture of 0.1% toluidine blue (Merck, Darmstadt,
Germany) and 2% paraformaldehyde (PFA, Merck) solution. Colonies containing > 50 cells
were counted as single-colony clusters. Total colony numbers were counted per flask by
light microscopy. The CFU-F number was repeated in 5 independent samples per each
experimental group. P1 cells (1 × 104 per well) were seeded on 2-well chamber slides
(Nunc) for 1–2 days, incubated with BrdU reagent (1:100, Invitrogen) for 24 hrs, and stained
with the BrdU staining kit (Invitrogen), following the manufacturer's instructions. Finally,
the cells were lightly stained with hematoxylin solution (Invitrogen). To quantify cell
proliferation capacity, we used 10 representative images to calculate BrdU-positive nuclei
numbers. Cell proliferation was shown as a percentage of BrdU-positive nuclei over total
nucleated cells. The BrdU assay was repeated with 5 independent isolated cells for each
experimental group.
Osteogenic and Adipogenic Differentiation Assays
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For in vitro osteogenesis assay, MSCs were cultured to confluence and changed to an
osteoinductive media containing 2mM β-glycerophosphate (Sigma-Aldrich Co.), 100 mM Lascorbic acid 2-phosphate (Wako Pure Chemical Industries Ltd.) and 10 nM Dex (SigmaAldrich Co.). After 4 weeks of osteo-inductive culture, calcium deposits were detected by
staining with 1% Alizarin Red (Sigma-Aldrich Co.). The mineralized areas were quantified
by using Image J and shown as a percentage of Alizarin Red-positive area over total area.
For the adipogenic induction assay, MSCs were cultured to confluence and then induced
under an adipogenic medium containing 500 μM isobutyl-methylxanthine, 60 μM
indomethacin, 0.5 μM hydrocortisone, and 10 μM insulin for 1 week. Cultures were stained
with 0.3% Oil Red-O after adipogenic induction. The number of Oil Red O-positive
droplets-containing cells were counted and shown as a percentage of Oil Red O-positive
cells over total cells. Three independent experiments were performed for each assay.

Calcif Tissue Int. Author manuscript; available in PMC 2013 December 04.
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Western Blot Analysis
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Total protein was extracted using M-PER mammalian protein extraction reagent (Thermo,
Rockford, IL). Twenty micrograms of protein were applied and separated on 4–12%
NuPAGE gel (Invitrogen Co.), followed by transferring to Immobilon™-P nitrocellulose
membranes (Millipore Inc.). Membranes were blocked with 5% non-fat dry milk and 0.1%
Tween-20 for 1 hour, followed by incubation with the primary antibodies (1:200–1000
dilution) at 4°C overnight. Horseradish peroxidase-conjugated IgG (Santa Cruz
Biotechnology; 1:10,000) was used to treat the membranes for 1 hour, followed by
enhancement with a SuperSignal® West Pico Chemiluminescent Substrate (Thermo,
Rockford, IL). Bands were detected on BIOMAX MR film (Kodak, Rochester, NY). Each
membrane was also stripped using a stripping buffer (Thermo) and reprobed with anti-βactin antibody to quantify the amount of loaded protein.
Flow Cytometric Analysis of Th17 and Tregs
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Cells collected from mouse spleens were treated with ACK lysis buffer (Lonza, Basel,
Switzerland) to remove red blood cells. 1−2 × 106 spleen cells were activated with 5 ng/ml
phorbol 12-myristate 13-acetate (PMA, Sigma-Aldrich Co.), 250 ng/ml ionomycin (SigmaAldrich Co.) and 1 μg/ml brefeldin A (GolgiPlug, BD) for 4 hours at 37°C and 5% CO2,
followed by incubation with 1 μg of PerCP-conjugated anti-CD4 antibody for 30 min on ice
under dark condition. For Treg analysis, additional 1 μg of APC-conjugated anti-CD25 was
added during the incubation. After cell fixation and permeabilization using Foxp3 staining
buffer kit, cells were stained with 1 μg of PE-conjugated anti-Foxp3 for Tregs and APCconjugated anti-IFN-γ/PE-conjugated anti-IL17 for Th17. Isotype-matched PE-, APC- or
PerCP- conjugated IgGs were used as controls. After washing with PBS/0.4%BSA for 3
times, cells were analyzed by using FACSCalibur flow cytometer (BD Bioscience).
Statistics
SPSS 13.0 was used to perform statistical analysis. Significance was assessed by analysis of
variance (ANOVA) followed by Tukey post-hoc test. The P values less than 0.05 were
considered significant.

Results
99Tc-MDP

Administration Ameliorates OVX-induced BMD Reduction
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Since osteoporosis is associated with overactivation of osteoclasts, we hypothesized
that 99Tc-MDP might ameliorate osteoporosis phenotypes by inhibiting osteoclast activity.
OVX mice, a reliable animal model for estrogen-deficient osteoporosis [2, 12, 15–16], were
used to examine the efficacy of 99Tc-MDP treatment (Fig. 1A). In terms of bone turnover
markers in serum, ELISA assays showed that RANKL levels were markedly decreased
after 99Tc-MDP and zoledronate administration, respectively, whereas OPG levels were
markedly increased compared with OVX group (Fig. 1B, 1C). MicroCT analysis showed
that 99Tc-MDP administration at 2 weeks post-OVX procedure significantly increased
BMD, BV/TV, Tb.Th and Tb.N in comparison to the untreated OVX group, to the extent
comparable to zoledronate (Fig. 1D-1H). Histological analysis indicated that trabecular bone
structures in 99Tc-MDP-treated OVX mice were significantly improved (Fig. 1I, 1J). Bone
resorption was markedly reduced after 99Tc-MDP treatment in OVX mice, as indicated by a
reduction in Oc.S/BS (Fig. 1K). Moreover, HE staining showed that 99Tc-MDP treatment
failed to impair kidney, liver and bladder (Supplementary Fig. 2), indicating that 99Tc-MDP
administration may be not toxic to OVX mice. These data suggest that 99Tc-MDP
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administration provides an effective treatment for OVX-induced osteoporosis by inhibiting
bone resorption.
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99Tc-MDP

Administration Increases Osteoblast Activity in OVX Mice
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Since osteoporosis associates with downregulated osteoblast activity, which is caused by the
osteogenic deficiency of BMMSCs [12, 17], we examined whether 99Tc-MDP
administration could elevate the osteogenic ability of BMMSCs in OVX mice. We harvested
BMMSCs and JBMSCs from OVX mice with/without 99Tc-MDP and zoledronate
administration, respectively. We found that both drugs reduced CFU-F and proliferation rate
in BMMSCs (Fig. 2A, B) and JBMSCs (Appendix Fig. 1A, B), respectively. In osteogenic
assay, both drugs increased mineralized nodule formation in BMMSC (Fig. 2C) and JBMSC
(Appendix Fig. 1C) groups, as measured by Alizarin Red staining and expression of the
osteogenic marker ALP, as shown by Western blot analysis (Fig. 2D, Appendix Fig. 1D).
This indicated that 99Tc-MDP treatment elevated the osteogenic capacity of MSCs by
sacrificing their proliferation rate in OVX mice. On the other hand, both 99Tc-MDP and
zoledronate treatments were able to significantly decrease the adipogenic differentiation
capacity of BMMSCs (Fig. 2E) and JBMSCs (Appendix Fig. 1E) derived from OVX mice,
as indicated by the decreased number of Oil Red O-positive cells and reduced expression of
the adipogenic genes PPARγ and LPL (Fig. 2F and Appendix Fig. 1F, p <0.05). Osteogenic
and adipogenic differentiation capacities between sham group and drug-treated groups
showed significant difference (p<0.05).
99Tc-MDP

administration diminishes the risk of BRONJ onset by maintaining balance
between Tregs and Th17
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Since 99Tc-MDP administration shows comparable therapeutic effects on ameliorating
osteoporotic phenotypes in OVX mice comparable to those of zoledronate-treated OVX
mice, we next asked whether 99Tc-MDP administration could avoid the risk of BRONJ
onset. We utilized a BRONJ animal model, as previously described [7], to test this
hypothesis. C57BL/6J mice were i.v.-injected with zoledronate or 99Tc-MDP (125 μg/kg)
and Dex (5 mg/kg) for 1 week before extraction of the first maxillary molar, and the drug
treatment continued twice a week until mice were sacrificed (Fig. 3 A). The maxillary bones
were evaluated for clinical signs of BRONJ lesions, following the guidelines established by
the American Association of Oral and Maxillofacial Surgeons (AAOMS) and the American
Society for Bone and Mineral Research (ASBMR) [18–20]. Clinical examination revealed
an incomplete mucosal healing and open sockets with exposed bone in 20% of mice treated
with zoledronate and 45% of mice treated with a combination of zoledronate and Dex (Fig.
3B, 3C). The finding of BRONJ in these treated mice was confirmed with histological study
revealing a lack of epithelial lining at the alveolar socket (Fig. 3C). Moreover, necrotic bone
was found adjacent to the area of intense inflammatory infiltrates, suggesting an association
between inflammation and tissue necrosis in BRONJ-like disease (Fig. 3C). In contrast,
100% of the 99Tc-MDP-treated mice, either with or without Dex, showed complete
epithelial coverage, which was confirmed by histological study (Fig. 3B, 3C). These data
indicated that cumulative dosage of zoledronate, but not 99Tc-MDP, may associate with
occurrence of BRONJ in mice undergoing dental extraction.
It has been proved that nitrogen-containing bisphosphates, e.g. zoledronate, are capable of
modulating both innate and adaptive immune responses [21–22]. Importantly, cumulative
high dosage of zoledronate can affect the Th17/Treg ratio, thus causing BRONJ-like disease
in mice [7]. Therefore, to clarify whether 99Tc-MDP treatment alters Treg/Th17 ratio, we
examined the levels of Tregs and Th17 cells in the spleens of mice at 2 weeks after tooth
extraction. Zoledronate only and zoledronate/Dex-treated mice showed a significantly
decreased level of CD4+CD25+Foxp3+ cells (Tregs) and increased level of CD4+IL17+ cells
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(Th17) in the splenetic cells compared with untreated control (Fig. 4A). However, 99TcMDP-treated groups, with or without Dex, neither significantly decreased the level of Tregs
nor increased Th17 levels (Fig. 4A). Consequently, the ratio of Tregs/Th17 was markedly
decreased in the zoledronate alone and zoledronate/Dex-treated group compared with
control and 99Tc-MDP–treated group (Fig. 4B). These findings suggest that 99Tc-MDP has
less risk of causing BRONJ onset in mouse model at the dosage of 125 μg/kg when
compared with zoledronate-treated group.

Discussion
To date, bisphosphonates are the most widely used antiresorptive drugs for osteoporosis.
However, BRONJ has become a major concern of bisphosphonate use [1, 6–8]. Although
the etiology of BRONJ remains unclear, it is believed that the pathogenesis results, in part,
from the suppression of the adaptive Tregs and activation of Th17 cells in newly established
BRONJ-like disease models [7, 23]. In order to characterize a novel bisphosphonate
derivative, 99Tc-MDP, we treated osteoporotic mice with it and assessed whether it could
induce BRONJ. Our data suggest that 99Tc-MDP ameliorates OVX-induced osteoporosis,
with effects comparable to zoledronate. Importantly, since 99Tc-MDP does not alter the
levels of Th17 cells or Tregs, it does not cause BRONJ-like disease in a mouse model.
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OVX mice are a reliable animal model for estrogen deficiency–induced osteoporosis [2, 12,
15– 16]. Since 8-week-old mice show comparable bone turnover markers with older adult
mice [24], they have been used as OVX mouse model in previous studies [14, 25–26]. It is
well established that osteoclastogenesis is a main cause in estrogen deficiency-induced
osteoporosis [3–4, 15], and evidences show that impairment of the osteoblast lineage also
contributes to the osteoporotic phenotype in OVX mice [12, 27–28]. In addition to the
already established understanding of the inhibition to osteoclast activity by bisphosphonates,
recent studies showed that bisphosphonates also stimulated osteoblast function [29]. In this
study, we demonstrate that both 99Tc-MDP and zoledronate inhibit bone resorption in OVX
mice and affect MSC functions, including inhibition of CFU-F numbers, proliferation rate
and adipogenic differentiation, whereas enhancement of osteogenic differentiation, which is
in accordance with previous studies [29, 30]. However, the significant differences between
sham group and drug-treated OVX groups indicate that the drugs can only partly rescue the
deficiency of MSC functions in OVX model by promoting the osteogenic commitment and
sacrificing their proliferation and adipogenic differentiation. Therefore, 99Tc-MDP, as a
bisphosphonate derivative, may share the same cellular mechanism of inhibiting bone
resorption, while stimulating MSC/osteoblast function.
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ELISA assay indicated that both 99Tc-MDP and zoledronate administration markedly
decreased RANKL levels in serum, whereas increased OPG levels compared with OVX
group in short term treatment, which is in accordance with a previously study in rats [31].
However, it has been proved that long term bisphosphonates treatment reduces bone
turnover, thereby resulting in increased risk of subtrochanteric femur fractures in
osteoporosis patients [32, 33]. These discrepant results may due to, at least in part, the length
of bisphosphonates treatment period and intra-specimen variations. Therefore, the long term
effects of 99Tc-MDP and zoledronate on the mouse model of OVX still await further
studies. Among the many potential risk factors, Treg/Th17 cells are important immune
components contributing to BRONJ onset in animal models [7]. Tregs can suppress various
immune responses and thus regulate immune homeostasis [34]. Tregs can also suppress
IL-17-producing Th17 cells, which play important roles in several autoimmune diseases,
including RA, systemic lupus erythematosus (SLE) or multiple sclerosis (MS) [35–37].
Using a newly developed BRONJ mouse model, we confirmed that zoledronate
administration could inhibit Tregs and activate Th17 cells, thereby causing BRONJ-like
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lesions at the site induced by dental extraction. Since most BRONJ patients are also
bisphosphonate-treated cancer patients who take immunosuppressant drugs, including Dex,
we tested the addition of Dex and found that zoledronate-induced BRONJ-like lesions were
enhanced. Since 99Tc-MDP has immunomodulatory properties manifested by
downregulation of proinflammatory cytokines, including TNF-α and IL1-β, ICAM-1, and
MMPs [9–10], it is reasonable to examine whether 99Tc-MDP regulates Tregs/Th17 cells.
Interestingly, in 99Tc-MDP-treated mice, with or without Dex, neither Tregs nor Th17 cells
were affected. Moreover, we didn't observe exposed bone in the group treated with 99TcMDP + Dex, suggesting that 99Tc-MDP may have less risk of causing BRONJ.
Over the decades, 99mTc-MDP has been used as a radioactive imaging agent for bone
scintigraphy. 99Tc-MDP, used in this study, has no radioactivity and is harmless to the
human body in long-term clinical treatment of systemic inflammatory diseases such as RA
[9]. 99Tc-MDP may be not toxic to mice, as observed no impairment in bladder, kidney and
liver. It is important to evaluate long-term effect of multi-dose administration of 99Tc-MDP
and elucidate the mechanism by which 99Tc-MDP differs from other bisphosphonates in the
context of Treg/Th17 ratio. To the best of our knowledge, this is the first study to show
that 99Tc-MDP is equipotent as zoledronate to prevent OVX-induced bone loss, with
minimal risks to cause BRONJ. However, whether 99Tc-MDP is effective for treatment of
bone loss in other diseases still awaits further study.
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In summary, we found that administration of 99Tc-MDP results in increased BMD in OVXinduced osteoporotic mice by inhibiting osteoclasts and enhancing osteogenic differentiation
of BMMSCs. Moreover, we showed that 99Tc-MDP, but not zoledronate, can avoid the
activation of Th17 cells and the suppression of Tregs in mice, thus preventing the onset of
BRONJ. Consequently, 99Tc-MDP therapy may be a promising approach in the treatment of
osteoporosis-associated bone resorption with less risk of causing BRONJ.
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Figure 1.
99Tc-MDP

administration ameliorates OVX-induced BMD reduction.
(A) Experimental design for OVX procedure and 99Tc-MDP (TC) or zoledronate (ZO)
treatment. (B, C) RANKL levels in peripheral blood were markedly decreased in both TCand ZO-treated groups compared with OVX group, whereas OPG levels were markedly
increased in both treatment groups. (D) MicroCT analysis showed the reduction of
trabecular bone volume in femurs of OVX mice. (E-H) TC administration significantly
improved BMD, Tb.Th, BV/TV and Tb.N. compared to untreated OVX mice. (I, J)
Histological analysis showed decreased trabecular bone volume (yellow circled area) in
femurs of OVX mice when compared to sham mice. TC treatment elevated trabecular bone
volume in OVX mice. (K) TRAP staining showed that Oc.S/BS was markedly decreased
after TC and ZO treatment compared to the OVX group. The results are presented as means
± SD. Scale bar, 0.2 mm. *p<0.05.
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Figure 2.
99Tc-MDP
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administration increases osteoblast activity in OVX mice.
(A) BMMSCs from TC-treated OVX mice generated fewer CFU-Fs compared to OVX
BMMSCs. (B) The number of BrdU-positive cells was significantly decreased in the TCtreated OVX group compared to the OVX group. (C) Alizarin Red staining showed that TC
treatment increased mineralized nodule formation. (D) Western blot analysis revealed that
BMMSCs from TC-treated mice expressed higher levels of ALP after 4 weeks of osteogenic
induction. (E, F) TC treatment decreased the adipogenic differentiation of BMMSCs, as
indicated by the decreased number of Oil Red O-positive cells and reduced expression of the
adipogenic genes PPARγ and LPL (scale bar, 100μm). The results were representative of
three independent experiments. *p<0.05.
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Figure 3.
99Tc-MDP

administration has less risk of causing BRONJ.
(A) Experimental procedure of inducing BRONJ. C57BL/6J mice were intravenously
injected with ZO or TC (125μg/kg) with/without Dex (5mg/kg) twice for 1 week before
surgical extraction of the maxillary first molar and continuous injection of ZO/TC and Dex
twice weekly for 2 weeks. (B) Incidence of BRONJ, manifested as an unhealed open socket
with exposure of bone. (C) Gross observation of gingiva at the extraction sites (open arrow)
at 2 weeks after tooth extraction. H&E staining showed the unhealed bone structure in the
ZO−treated group, but not the TC group. B, Newly formed bone; CT, connective tissues,
NB, necrotic bone. Bottom panel: magnification of the middle panel. Scale bar, 100μm.
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Figure 4.
99Tc-MDP,

but not zoledronate, keeps the balance between Tregs and Th17 in the BRONJ
model.
(A) Flow cytometric analysis showed significantly decreased CD4+CD25+Foxp3+ cells
(Tregs) and increased CD4+IL17+ cells (Th17) in the splenetic cells from ZO only and ZO
+Dex-treated mice compared with untreated control or TC groups. (B) The Treg/Th17 ratio
in spleens of C57BL/6J mice after receiving TC treatment was significantly higher than that
with ZO treatment. The results were representative of three independent experiments.
*p<0.05.
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